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Hematopoietic stem cells have been identified as mul-
tipotent cells that give rise to all adult hematopoietic
lineages. Although the hematopoietic lineage is derived
from the mesodermal germ layer in the embryo, recent
data suggest that bone marrow cells with an antigenic
profile consistent with that of hematopoietic stem cells
can also differentiate to cell types of the endodermal
lineages, such as hepatocytes. However, the molecular
mechanisms associated with these events are entirely
unknown. For decades, -fetoprotein (AFP) has been
used as a differentiation marker for endodermal cells,
because it was thought that the transcription of AFP
mRNA is tightly regulated in a developmental and tis-
sue-specific process. In this report we describe two new
variant forms of AFP transcripts in human hematopoi-
etic progenitors that are not expressed in mature cells.
The variant AFP (vAFP) cDNA sequences isolated from a
multipotent hematopoietic cell line, K562, revealed that
the vAFP differed from the authentic transcript, consist-
ing of 15 exons, by replacing exon 1 of AFP with one or
two exons located in the 5-untranslated region of the
AFP gene. In addition to the K562 cell line, vAFP tran-
scripts were detected in normal bone marrow, thymus,
and brain but were not detected in normal spleen, intes-
tine, liver, or the hepatocellular carcinoma cell line,
HepG2. This suggests expression in normal hematopoi-
etic progenitors. This hypothesis was confirmed by the
finding that CD34Lin hematopoietic progenitor cells
purified from cord blood by flow cytometric sorting also
expressed the variant transcripts. These results suggest
that some hematopoietic progenitors are in a state that
permits them to express certain types of transcripts that
have been considered unique to endoderm.
Stem cells, pluripotent cells capable of extensive growth
without losing their multipotentiality, are becoming the cen-
terpieces of new strategies for cell therapies, gene therapies,
and tissue engineering, all contributing to a new era in medi-
cine (1–3). The molecular machinery of self-renewal and differ-
entiation is one of most intriguing subjects of stem cell biology.
Analyses of gene expression patterns using subtracted cDNA
library or cDNA microarray techniques have revealed several
candidates of new or known transcripts that are expressed
exclusively in stem cell populations, but not in terminally dif-
ferentiated cells (4, 5). These studies provide enormous infor-
mation facilitating the development of approaches for under-
standing stem cells. However, the applied techniques have an
intrinsic weakness in that they cannot detect the stem/progen-
itor cell-specific isoforms of transcripts having relatively long
domains in common between the isoforms. Therefore, an alter-
native strategy is to analyze individual genes with expression
that is regulated in developmentally specific ways in particular
cell lineages.
Cell differentiation in the developing embryo is regulated by
extrinsic inductive signals and an intrinsic programmed ge-
netic code. Differentiation into the three germ layers (ecto-
derm, endoderm, and mesoderm) from primitive ectoderm (epi-
blast) is a crucial step during development and thought to be an
irreversible process. This leads to the development of unique
cell types from each germ layer, e.g. epidermal or neuronal cells
from ectoderm; epithelial cells in internal organs or digestive
tract from endoderm; and hematopoietic and mesenchymal
cells from mesoderm. Recent studies (6, 7) of cell transplanta-
tion, however, suggest that somatic stem or progenitor cells
from adult tissues are able to generate cells with fates different
from those normally associated with the germ layer that gave
rise to the stem cells. A typical example of so-called “transdif-
ferentiation” is that of murine bone marrow-derived
ckithighThylowLinSca-1 cells giving rise to mature hepato-
cytes (8). This antigenic profile is used to define hematopoietic
stem cells. Although reports about these examples of possible
transdifferentiation in mammals are accumulating (9), it re-
mains to be determined whether the studies observed transdif-
ferentiation or identified more primitive progenitors than he-
matopoietic stem cells in bone marrow. In addition, recent
reports proposed that spontaneous cell fusion between trans-
planted donor progenitors and recipient cells might cause mis-
interpretation in previous studies reported as possible trans-
differentiation (10, 11). In any event, biochemical analyses are
necessary for understanding multipotency of the cells not only
in those experimental setting but in normal physiological
environment.
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Adult liver parenchymal cells consist of hepatocytes and
biliary epithelial cells. They are derived from common precur-
sors, hepatoblasts, during embryonic development (12). The
bipotent progenitors originate from multipotent endodermal
cells in the foregut by inductive signals from the septum trans-
versum surrounding the outgrowth of the endoderm (13). Al-
though it is not known whether the bone marrow-derived cells
can differentiate into hepatoblasts or can convert directly to
hepatocytes, the cells possessing potential for hepatic differen-
tiation should express some early endodermal markers before
full differentiation into hepatocytes.
One such marker is -fetoprotein (AFP),1 which is a major
serum protein produced primarily by visceral endoderm of
the yolk sac and by hepatoblasts as well as more differenti-
ated fetal hepatic cells (14, 15). AFP is one of the earliest
markers for endodermal differentiation; the transcriptional
expression starts with the appearance of visceral endoderm
in the early embryo and is regulated tightly by developmental
and tissue-specific cues (14–16). Therefore, in most studies
that assess endodermal differentiation of human embryonic
stem cells or embryonic germ cells, the expression of AFP
transcripts or the products have been used as a marker of
endoderm (17–19).
In this study, we have identified two variant forms of human
AFP transcripts from a multipotent hematopoietic cell line,
K562. The cDNA sequences revealed that the differences in the
variant AFP (vAFP) mRNAs from that of the authentic tran-
script, which consists of 15 exons, is the presence of one or two
unique exons, named exon A and exon B, replacing exon 1 of
AFP. The variant forms were detected in normal CD34Lin
hematopoietic progenitor cells but not in mature blood cells.
The expression of the variant AFP transcripts suggests that
hematopoietic progenitors are in a state that permits them to
express certain types of transcripts that have been considered
unique to the endoderm.
EXPERIMENTAL PROCEDURES
Cell Culture—The human hepatoblastoma cell line, HepG2, was
maintained in Eagle’s MEM supplemented with 1 mM sodium pyru-
vate, 2 mM L-glutamine, 50 units/ml penicillin, 50 g/ml streptomy-
cin, 0.1 mM MEM non-essential amino acids solution, 5 g/ml insulin,
and 10% fetal bovine serum. The human erythroleukemia cell line,
K562 was maintained in DMEM/F12 supplemented with 2 mM L-
glutamine, 50 units/ml penicillin, 50 g/ml streptomycin, 5  105 M
2-mercaptoethanol and 10% fetal bovine serum. HepG2 and K562
were obtained from the Tissue Culture Core Facility of the Cancer
Center at the University of North Carolina at Chapel Hill. Normal
human fetal lung fibroblasts, MRC5 (American Type Culture Collec-
tion), were cultured in the same supplemented DMEM/F12 in the
presence of 10% horse serum (Sigma) and 1 ng/ml of bovine FGF-2
(Collaborative Biomedical Research).
Polymerase Chain Reaction—The primer sequences used for PCR are
shown in Table I. For reverse transcriptase-PCR (RT-PCR), total RNAs
were extracted from various cell lines and subjected to cDNA synthesis.
Briefly, cDNAs were synthesized from 10 g of total RNAs by oligo(dT)
priming and AMV reverse transcriptase (Seikagaku) in a reaction vol-
ume of 20 l at 42 °C. PCR was performed in a total volume of 50 l
consisting of 1 M each primer, 200 M each dNTP, 50 mM KCl, 1.5 mM
MgCl2, 10 mM TrisHCl, pH 8.3, and 1.25 units of Amplitaq polymerase
gold (PerkinElmer Life Sciences) with synthesized cDNA. Samples were
heated to 94 °C for 3 min followed by amplification for 30 cycles for AFP
or 35 cycles for vAFP of 2 min at 94 °C, 2 min 62 °C, and 3 min at 72 °C.
After the last cycle, a final extension step was done at 72 °C for 6 min.
Then 5 l of each PCR reaction were analyzed by 1% agarose gel
electrophoresis. For nested RT-PCR of AFP or vAFP in various human
tissues, one-fourth of the cDNA synthesized from 10 g of total RNAs
(CLONTECH) were used for the first PCR. One-hundredth of the vol-
ume of the first PCR product was applied for nested PCR using an
internal primer set. The PCR consisted of 1 cycle of 3 min at 95 °C; 30
cycles of 1.7 min at 95 °C, 2 min at 62 °C, 1.5 min at 72 °C followed by
a 4.5 min extension at 72 °C. Then, 5 l of each sample were analyzed
in 2% agarose gels. For RT-PCR of sorted cells from human umbilical
cord blood cells, total RNA was isolated with RNeasy kit (Qiagen).
cDNAs synthesized from total RNAs of sorted cells were normalized by
the cell number. Nested PCR for vAFP was performed with cDNA
equivalent to 48,000 cells. Single step RT-PCR for -actin or CD34 was
done with cDNA equivalent to that of 1000 cells. For analysis of the
genomic sequence of exon A, genomic DNAs were isolated from HepG2,
K562, and MRC5 with QIAamp Tissue Kit (Qiagen). Amplified PCR
products, using g-ex-AS and g-ex-AA primers (Table I), were cloned into
pCRII-TOPO (Invitrogen), and the DNA sequences were determined by
the DNA sequencing core facility of the University of North Carolina at
Chapel Hill (Dr. Laura Livingston, director).
Identification of the 5-End of Variant AFP Transcripts—The rapid
amplification of cDNA ends (RACE) method (14) was performed with
modifications to identify the 5-end of the vAFP transcripts. Briefly,
with terminal transferase (Roche Molecular Biochemicals), a poly(dG)
tail sequence was introduced into K562 cDNA derived from 10 g of
total RNA. One-tenth volume of the cDNA was amplified for the first 5
cycles with 94 °C for 1 min, 45 °C for 1.5 min, and 72 °C for 2.5 min,
followed by 15 cycles with 94 °C for 1 min, 60 °C for 1.5 min, and 72 °C
for 2.5 min using SN-poly(C) primer and ex-2A, ex-3A, or ex-4A. PCR
products purified with QIAquick PCR purification kit (Qiagen) were
reamplified with SN primer and an internal AFP primer (ex-1A, ex-2A,
or ex-3A) at 94 °C for 1 min, 62 °C for 1.5 min, and 72 °C for 2.5 min for
30 cycles. The final PCR products were cloned into pCRII-TOPO and
sequenced.
Umbilical Cord Blood (UCB) Cell Preparation and Fluorescence-
activated Cell Sorting—Human UCB was obtained from the Carolina
Cord Blood Bank following institutional review board-approved in-
formed consent. UCB was processed as described (27). Unfractionated
nucleated UCB cells were prepared by deleting red blood cells with the
use of Hespan (DuPont Pharma, Wilmington, CE) and hemolysis at
37 °C in 0.17 M NH4Cl, 20 mM Tris-HCl, pH 7.2, and 200 M EDTA.
Lineage-committed cells were removed from the unfractionated cells
using the StemSep enrichment system (progenitor mixture, StemCell
Technologies Inc, Vancouver, British Columbia). The recovered cells
were termed Lin UCB cells. Cells were purified using a FACStar Plus
cell sorter (Becton Dickinson Immunocytometry Systems (BDIS), San
Jose, CA). For cell sorting, the Lin UCB cells were stained with a
mixture of three phycoerythrin (PE) conjugated CD34-specific antibod-
ies (clones Qbend10, Immu133 and Immu409, Beckman Coulter,
1 The abbreviations used are: AFP, -fetoprotein; vAFP, variant -fe-
toprotein; RACE, rapid amplification of cDNA ends; UCB, umbilical
cord blood; MEM, minimal essential medium; DMEM, Dulbecco’s MEM;
RT-PCR, reverse transcriptase-PCR; PE, phycoerythrin; 7AAD, 7-ami-
noactinomycin D.
TABLE I
Primer sequences used in this study
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Miami, FL). For all cell sorting, (7-aminoactinomycin D (Molecular
Probes; 7AAD) was used to exclude dying cells. This was added to a final
concentration of 10 g/ml during the antibody incubations. In some
instances, the expression of CD38 was also monitored (clone HB7,
BDIS).
RESULTS
Variant AFP mRNA Expressed in K562, a Human Erythro-
leukemia Cell Line—The human AFP gene consists of 15 exons
(Fig. 1A). The coding sequence is from exon 1 to exon 14 (20). To
investigate the expression of possible variant forms of AFP
mRNA in hematopoietic cells, two different portions of the AFP
cDNA sequence were selected as target sequences of RT-PCR.
The primer combination of ex-1S and ex-3A was used to am-
plify exon 1 containing the initiation methionine to exon 3, and
the combination of ex-12S and ex-14A was used to amplify exon
12 to exon 14 containing the termination codon (Fig. 1B). The
results of the PCR are shown in Fig. 2A. Both combinations of
the primers resulted in intense amplification bands in the
cDNA from HepG2, a hepatocellular carcinoma cell line (lanes
1 and 2). By contrast, cDNA from the erythroleukemia cell line,
K562, showed an amplification band only for the C-terminal
portion, identified by the ex-12S and ex-14A (lane 5) whereas
there was no band by PCR of the primer combination of ex-1S
and ex-3A (lane 4). This result suggests that K562 expresses a
short form of authentic AFP transcript without the N terminus.
In fact, the result of the PCR for the whole coding region of AFP
using ex-1S and ex-14A primers showed that the single band of
1.8 kb (lane 3) was amplified from the HepG2 cDNA, whereas
there was no detectable band in K562 (lane 6).
The AFP genes in rats, mice, and humans are organized
similarly into 15 coding exons interrupted by 14 introns (20–
22). Although there has been no report about any variant form
of the AFP mRNA in humans, several short forms of the AFP
transcript have been characterized in rats (23, 24). The rat
vAFP lacks the first six or seven exons, but shares common
3-sequences containing the seventh or eighth exon to the fif-
teenth exon, respectively (23). Detailed analysis of one variant
form of rat showed that the rat vAFP used an additional exon,
designated as exon V that is located in the seventh intron of the
rat gene, as the first exon of the variant form. However, it
turned out that human vAFP transcripts in K562 had different
structures from the rat vAFP because RT-PCR of the primer
combination exon 7 and ex-14A could detect the variant tran-
scripts (data not show). Therefore, a series of 5-primers from
exon 2 to exon 6 were constructed (Fig. 1B) to see the difference
between authentic and variant forms of AFP transcripts in
K562. With each of these, ex-14A primer was used as a 3-
primer. The results of the RT-PCR showed, intriguingly, that
human variant AFP transcripts in hematopoietic cells share
the entire coding exons, except for exon 1, in the authentic form
that is expressed in HepG2 (Fig. 2B). Recently, it has been
reported that an AFP isoform using a new exon located in
intron 1 is expressed preferentially in the yolk sac and fetal
liver in the mouse (25). However, no detectable amplified band
in the PCR using an intron 1-specific 5-primer (data not
shown) suggested that the human vAFP transcripts in hema-
topoietic cells are novel isoforms of AFP.
Molecular Cloning of Variant AFP cDNA from K562—To
determine the sequences of the 5-end of the vAFP transcript in
K562, the RACE method was applied as described under “Ex-
perimental Procedures.” As a result, two types of variant tran-
scripts were identified. The sequences are shown in Fig. 3A.
Comparing the sequences of the variant transcripts to the
GenBankTM data base, two regions of genomic sequence of the
human AFP gene were identified. One type (type A) of the
variant forms used an additional exon, designated as exon A,
located about 5 kb upstream from exon 1 (Fig. 3B). The other
type (type AB) used exon A in conjunction with another exon,
designated as exon B, located about 1.6 kb upstream from exon
FIG. 2. Expression of AFP mRNAs in K562 and HepG2 was
analyzed by RT-PCR. A, primer combination of ex-1S and ex-3A
(lanes 1, 4, and 7), ex-12S and ex-14A (lanes 2, 5, and 8), or ex-1S and
ex-14S (lanes 3, 6, and 9) was used to amplify exon 1 to exon 3, exon 12
to exon 14, or exon 1 to exon 14 of AFP cDNA, respectively. B, series of
5-primers from exon 1 to exon 6 (ex-1S to ex-6S) and ex-14A as the
3-primer were used to detect AFP transcripts. Lanes 1, 3, 5, 7, 9, and
11 for K562. Lanes 2, 4, 6, 8, 10, and 12 for HepG2. The amount of
HepG2 cDNA was one-hundredth of that from K562. The right panel in
A and B shows expression of -actin. A, lane 10, HepG2; lane 11, K562;
and lane 12, control. B, lane 13, HepG2; lane 14, K562; and lane 15,
control. Open triangle indicates 1 kbp.
FIG. 1. Schematic representation of
the human AFP gene, AFP transcript,
and position of primers used for RT-
PCR. A, human AFP gene consists of 15
exons and 14 introns and spans 20,000
base pairs. The initiation methionine
codon (ATG) and the termination codon
(TAA) of the AFP transcript are indicated
in exon 1 and exon 14, respectively. B,
approximate position of sense primers
and antisense primers are shown. The nu-
cleotide sequences of primers were de-
scribed in Table I.
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1 (Fig. 3B). Among 19 clones analyzed in these experiments, 15
clones were type A; 3 clones were type AB; and one clone was
the germ line transcript of intron 1. Although the genomic
sequences containing exon A were reported originally from
Watanabe et al. (26), some nucleotides in the exon A of K562
differed from the genomic sequence (Fig. 3A, underline). First,
to determine whether this difference arose from artifacts asso-
ciated with the anchored PCR technique, the genomic sequence
of exon A in K562 cells was compared with the cloned cDNA
sequence. This showed that the cDNA and genomic DNA of
K562 cells were identical (data not shown). Next, to determine
whether the genomic sequence of exon A of K562 is specific for
the cell line, the genomic sequence of HepG2 and normal hu-
man fibroblasts, MRC5, was compared with that of K562. The
results indicated no difference in the genomic sequence from all
three sources, K562, HepG2, and MRC5 (data not shown). In
addition, the genomic DNA sequence on the AFP locus from the
data base of the human genome project (GenBankTM; accession
no. AP002825) corresponded with the sequences of K562. These
results suggest that the DNA sequence of exon A cloned from
K562 does not include artifacts from the PCR cloning.
Selective Expression of Variant Transcripts in K562—The
expression pattern of the variant and authentic transcripts of
AFP was studied in K562 and HepG2. A sense primer of exon
A for RT-PCR was designed. The combination of the exon A
primer, ex-AS, and exon 14 primer, ex-14A, successfully de-
tected the transcripts in K562, but not HepG2 (Fig. 3C). The
amplified products from K562 were cloned and sequenced. As
expected, the two types of variant AFP transcripts either using
both exons A and B or exon A alone were followed by exon 2 to
exon 14. The number of clones with a type A sequence was 7 of
12, while that of type AB clone was 5 of 12 (data not shown).
This suggests that the two types of vAFP are expressed equally
in K562. The far stronger signal of HepG2 by RT-PCR using
ex-2S and ex-14A indicated that HepG2 expressed the authen-
tic form only. This result demonstrated clearly that the expres-
sion pattern of variant and authentic forms of AFP rigorously
discriminates between K562 and HepG2 cells.
Expression of Variant Forms of AFP in Normal Human Tis-
sues—We next examined whether the variant transcripts of
AFP are expressed in normal cells. Since we anticipated the
expression in normal cells would be at very low levels, a nested
(two step) RT-PCR was performed. The first PCR was per-
formed with primers, ex-A1S and ex-14A, to amplify the whole
coding sequence of variant forms. Subsequently, nested PCR
was performed by an internal primer combination, ex-A2S and
ex-3A, which can distinguish between the presence of type A
and type AB by the molecular size (Fig. 4A). The PCR results
indicate that the tissue distribution of the vAFP transcripts is
fairly restricted. Only primary hematopoietic organs, bone
marrow (lane 1) and thymus (lane 2), and brain (lane 7) ex-
pressed the transcripts. Other tissues, including liver, lung,
trachea, kidney, stomach, small intestine, colon, heart, and
spleen, did not have cells expressing vAFP. These results
strongly suggest that hematopoietic progenitors, but not ma-
ture blood cells, express vAFP, because the spleen is a second-
ary hematopoietic organ in which hemato-lymphopoiesis does
not take place under normal physiological conditions. In addi-
tion, cDNA from peripheral blood cells (CLONTECH) never
showed the expression of vAFP (data not shown). On the other
hand, authentic AFP was detected in brain, kidney, small in-
testine, and thymus, but not in bone marrow. No expression in
normal human fetal fibroblasts (lane 13) or small intestine
(lane 4) suggests that the vAFP expression is not associated
simply with cell proliferation.
Variant Transcripts of AFP Expressed in Hematopoietic Pro-
genitors—The RT-PCR of tissue RNAs cannot define which
cells express the variant forms of AFP transcripts. Bone mar-
row and thymus consist of a very heterogeneous cell popula-
tion. Therefore, we studied purified hematopoietic progenitors
from UCB by flow cytometric sorting to learn whether or not
they express vAFP. Unfractionated nucleated cells in UCB
contain only small numbers of CD34 cells (Fig. 5A) in which
hematopoietic progenitors are highly enriched (27). The CD34
UCB cells could be enriched after removing Lin-positive cells
(Fig. 5A). Both live (7AAD), unfractionated cells and
CD34Lin cells were isolated by flow cytometric sorting, and
the RNAs extracted were subjected to nested PCR for vAFP. A
total of four different cord bloods were tested. As shown in Fig.
5B, the expression of vAFP transcripts was detected in
CD34Lin cells, enriched hematopoietic progenitors (lanes 2,
4, 6, and 8; 4 of 4), but not in unfractionated cord blood cells
FIG. 3. Molecular structure and expression of vAFP. A, DNA
sequences of two variant forms of AFP transcripts isolated from K562
cDNA. B, schematic illustration of genomic structure of variant AFP.
Open boxes and horizontal lines indicate exons and introns, respec-
tively. Their lengths in nucleotides are indicated by numbers above or
below these elements. One type of the variant forms used one additional
exon (exon A) located 5-kb upstream from exon 1. The other type used
exon A and another exon (exon B) located 1.6 kb from exon 1. Genomic
organization of the variant forms was deduced from genomic sequence
of the AFP gene. C, selective expression of variant AFP transcripts in
K562. RT-PCR of primer combination of exon A primer (ex-AS) and
ex-14A primer were performed with cDNA from K562 (lane 1) and
HepG2 (lane 2). K562, but not HepG2, expressed variant forms of AFP
transcripts. The strong signal of HepG2 by RT-PCR using ex-2S and
ex-14A indicates that HepG2 expresses the authentic form only. Equal
amounts of cDNA were used for the reaction. Lane 3, control reaction.
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(lanes 1, 3, and 5; 3 of 4). Cloning and DNA sequencing exper-
iments showed that the amplified bands corresponded to cDNA
sequences of type A and type AB from K562 cells (data not
shown). CD34 expression in the sorted CD34Lin cells was
confirmed by RT-PCR (Fig. 5B).
DISCUSSION
The present study identified two variant forms of AFP ex-
pressed preferentially in hematopoietic progenitors, but not in
mature blood cells or in hepatic cells. These results suggest
that the AFP gene locus of chromatin in hematopoietic progen-
itors is open and accessible to transcription factors for the
mRNA expression. In other words, chromatin-related repres-
sion of authentic AFP, which is a mechanism that will block
inappropriate expression of authentic AFP in non-hepatic cells
(28), is incomplete in hematopoietic progenitors and allows
vAFP to be transcribed. In the case of K562, strictly speaking,
very small amounts of authentic AFP transcripts could be
detected when cycles of RT-PCR were increased (Fig. 4B, lane
14). This indicates that K562 express vAFP at a much higher
level than authentic AFP. Conversely, vAFP could be detected
in HepG2 by increasing cycles of RT-PCR (data not shown).
Therefore, our data derived from the cell lines suggest that
three types of patterns are present with respect to the authen-
tic and variant transcripts of AFP. Hepatic cells (HepG2) ex-
press authentic AFP dominantly, while hematopoietic cells
(K562) express vAFP dominantly. Fibroblasts (MRC5) express
neither authentic AFP nor vAFP. This prompts us to ask two
questions with respect to AFP expression. 1) What is the mech-
anism of the opening of the AFP locus in the chromatin, giving
rise to whichever of the transcripts is expressed? 2) What is the
transcriptional machinery associated with the different
transcripts?
The mouse has proved an excellent model system for study-
ing tissue-specific and developmentally regulated transcrip-
tional control of authentic AFP in vivo as well as in vitro
(14–16). Extensive studies have established that the transcrip-
tional control of the AFP gene is mediated by five cis-acting
regulatory domains, including the AFP promoter, three distinct
FIG. 5. Expression of variant AFP transcripts in normal hu-
man hematopoietic prgenitors. A, representative dot plot of flow
cytometry for CD34 and CD38 expression in UCB cells after ficoll
centrifugation are shown at the left. CD34 cell population was 2.3% on
the average. CD34 cell population was enriched after removing Lin
cells. Live CD34 cell fraction (inside of open box) was sorted for RT-PCR
analysis. B, RT-PCR analyses of variant AFP transcripts of sorted UCB
were performed as described in the legend to Fig 3. Roman numerals
indicate individual UCB samples. Lanes 1, 3, 5, and 7, unfractionated
UCB cells; lanes 2, 4, 6, and 8, CD34Lin UCB cells; lane 9, K562; lane
10, control reaction.
FIG. 4. RT-PCR analyses of variant
AFP transcripts in normal human tis-
sues. A, nested PCR strategy. First PCR
(PCR-1) of primer combination of ex-A1S/
ex-14A and second PCR (PCR-2) of that of
ex-A2/ex-3A are illustrated. The ampli-
fied DNA fragments of two AFP variant
forms were distinguishable in agarose
electrophoresis. B, expression of variant
AFP mRNAs was analyzed in cDNAs
from various human tissues. Lane 1, bone
marrow; lane 2, thymus; lane 3, spleen;
lane 4, small intestine; lane 5, colon; lane
6, stomach; lane 7, brain; lane 8, heart;
lane 9, kidney; lane 10, liver; lane 11,
lung; lane 12, trachea; lane 13, MRC5;
lane 14, K562; and lane 15, no template.
Nested RT-PCR of the authentic AFP
transcript was performed with the same
human tissues cDNAs. Primer combina-
tion of ex-1capS/ex-14A for first PCR and
that of ex-1S/ex-3A for second PCR were
used. The result from single step RT-PCR
of -actin is shown at the bottom. Open
and closed triangles indicate 500 or 1000
bp of the ladder marker, respectively.
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enhancer elements, and one repressor region located between
the AFP promoter and the upstream enhancers (reviewed in
Ref. 29). There are a number of transcription factors binding to
the promotor region to control the expression of the authentic
AFP form (reviewed in Ref. 29). It has been proposed that
GATA factors, especially GATA4, could be a master gene for
endodermal differentiation (30) and for the expression of feto-
protein transcription factor, which activates AFP expression in
early liver development (31). On the other hand, other GATA
factors are key regulators for hematopoiesis (32). Interestingly,
several possible GATA family binding sites were identified in
the exon A genomic sequence as well as other transcription
factor binding sites associated with hematopoiesis such as
AML-1 (33) and MZF-1 (34). Because exon A was identified as
only one 5-end of two variant forms by our RACE method in all
independent clones, exon A is possibly the first exon of vAFP in
K562. Thus, it is noteworthy to see whether these transcription
factors expressed in hematopoietic progenitors are involved in
the transcription of vAFP. However, the transcriptional start
site of the variant forms of AFP in hematopoietic cells remains
to be determined.
Although extensive research has been performed to elucidate
AFP gene regulation in various species (15, 35), there has been
no report about human variant AFP transcripts nor identifica-
tion of exon A and exon B 5-upstream of exon 1 in any species.
Variant AFP transcripts identified in rodents were expressed
preferentially in hepatic or yolk sac cells (24, 25). These suggest
that the vAFP transcripts in the human hematopoietic cells are
different from ones identified in rat or in mouse not only in
their molecular structures, but also in their expression pattern.
Interestingly, all variant forms of AFP reported in the previous
studies and this study use unique first exons. Because the
different usage of the first exon suggests that the vAFP expres-
sion is dependent on a unique promotor (24, 25), further studies
are required to elucidate the hematopoietic cell-specific promo-
tor of vAFP.
At present, apart from the hematopoietic organs, the brain is
the only tissue where vAFP expression is observed. It has been
shown that cultured neurospheres, which are considered as
neural stem cells, isolated from the anterior portion of the
lateral wall of the lateral ventricles in adult mice were able to
differentiate to endodermal cells (36). Therefore, it is important
to determine the identity of vAFP cells in the brain and isolate
them from brain tissue in order to ask whether they have a
capability to form neurospheres in vitro. The expression of
vAFP in non-endodermal cells may represent a unique imma-
ture state, which has the developmental potential of endoder-
mal cells.
The function of the vAFP is unclear because the amount of
mRNA was extremely low, and no protein products were ever
found in assays using immunohistochemistry with anti-AFP
antibodies on hematopoietic progenitors.2 In addition, there is
no long open reading frame starts in exon A or B to connect
with exon 2 of authentic AFP if only ATG is considered as an
initiation codon. In that case, a possible initiation codon at exon
3 would be used for the translation so that the translated
product from vAFP transcripts would be a truncated form.
However, because there is TTG and CTG in exon B to connect
the open reading frame of exon 2, it might be possible for one of
them to work as an alternative initiation codon (37, 38). In any
event, further studies are required to elucidate the possible
functions of vAFP transcripts.
As a final point, this study raises a warning about the use
of RT-PCR techniques for the detection of AFP mRNA. AFP is
used commonly as a molecular marker for endodermal differ-
entiation (17–19) or certain carcinomas such as hepatomas or
germ cell tumors (15, 35). Various RT-PCR techniques have
been developed for the detection of circulating carcinoma
cells in peripheral blood (39). Nevertheless, none of them, to
the best of our knowledge, used exon 1-specific primers to
detect the authentic form of AFP. Thus, the use of not only
the exon 1-specific primer but the exon A-specific primer for
RT-PCR to analyze AFP mRNA expression will be necessary
to consider which types of transcripts are expressed in the
cells examined.
In conclusion, this is the first study in which variant forms of
an endodermal marker, AFP, have been found, with a selective
pattern of expression in human hematopoietic progenitors. Our
results suggest that the expression of vAFP transcripts may
reflect the ability of progenitors for hematopoietic cells to dif-
ferentiate to endodermal cells and provides a unique opportu-
nity for studying the mechanism.
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